Drug Information

Drug (ID: DG02013) and It's Reported Resistant Information

• Name: BAY2402234
• Synonyms: KNVJMHHAXCPZHF-JTQLQIEISA-N; BAY-2402234; SCHEMBL20108031; HY-112645; CS-0058850
• Indication:
  In total 1 Indication(s)
  Myeloid leukaemia [ICD-11: 2B33]; Phase 1
• Target: Dihydroorotate dehydrogenase (DHODH); PYRD_HUMAN
• Formula: 94.5
• IsoSMILES: KNVJMHHAXCPZHF-JTQLQIEISA-N
• InChI: CCN1C(=NN(C1=O)C2=C(C=C(C(=C2)O[C@@H](C)C(F)(F)F)C(=O)NC3=C(C=CC=C3Cl)F)F)CO
• InChIKey: N-(2-chloro-6-fluorophenyl)-4-[4-ethyl-3-(hydroxymethyl)-5-oxo-1,2,4-triazol-1-yl]-5-fluoro-2-[(2S)-1,1,1-trifluoropropan-2-yl]oxybenzamide
• PubChem CID: 134470179
• TTD Drug ID: D08DMH

Type(s) of Resistant Mechanism of This Drug

  MRAP: Metabolic Reprogramming via Altered Pathways

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Brain cancer [ICD-11: 2A00]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Metabolic Reprogramming via Altered Pathways (MRAP)

Key Molecule: Dihydroorotate dehydrogenase (DHODH) [1]

• Metabolic Type: Nucleic acid metabolism
• Sensitive Disease: Glioblastoma [ICD-11: 2A00.02]
• Molecule Alteration: Expression; Up-regulation

Differential expression of the molecule in resistant disease

• Classification of Disease: Brain cancer [ICD-11: 2A00]
• The Specified Disease: Glioblastoma
• The Studied Tissue: Nervous tissue
• The Expression Level of Disease Section Compare with the Healthy Individual Tissue: p-value: 7.05E-05; Fold-change: 3.01E-01; Z-score: 4.81E+00
• Experimental Note: Identified from the Human Clinical Data
• In Vivo Model: HCC patients; Homo Sapiens
• Experiment for Drug Resistance: Cell viability assay
• Mechanism Description: Recently, the dihydroorotate dehydrogenase (DHODH) inhibitor BAY2402234 displayed efficacy in different brain cancer animal models

References

• Ref 1: Metabolic Plasticity of Glioblastoma Cells in Response to DHODH Inhibitor BAY2402234 Treatment. Metabolites. 2024 Jul 27;14(8):413.